By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aridis Pharmaceuticals 

5941 Optical Court

San Jose  California  95138  U.S.A.
Phone: 408-385-1742 Fax: 408-960-3822




Company News
Aridis Pharmaceuticals Receives FDA Fast Track Designation For AR-301 For Acute Pneumonia Caused By Staphylococcus Aureus 9/11/2015 6:52:03 AM
Aridis Pharmaceuticals Appoints Fred Kurland As Chief Financial Officer 7/14/2015 6:48:31 AM
Aridis Pharmaceuticals Expands Phase 2a Trial Into The U.S. For Monoclonal Antibody AR-301 For The Treatment Of Acute Pneumonia 7/8/2015 6:34:42 AM
Aridis Pharmaceuticals Receives FDA Fast Track Designation For Aerucin For Treating Hospital-Acquired And Ventilator-Associated Pneumonia 6/30/2015 11:03:55 AM
Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, To Board Of Directors 4/9/2015 9:15:40 AM
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015 11:12:04 AM
Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., As Chief Medical Officer 3/23/2015 9:13:24 AM
Aridis Pharmaceuticals Appoints Dr. Steven Opal To Scientific Advisory Board 12/1/2014 12:07:14 PM
Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 5/17/2013 9:25:33 AM
EnWave Corporation (ENW.V) and Aridis Pharmaceuticals Sign Collaboration Agreement-Relationship Expanded to Include Antibodies 7/11/2007 9:07:34 AM